COMMUNIQUÉS West-GlobeNewswire

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
20/11/2025
BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of [...]
Informations sur le nombre total de droits de vote et d'actions
20/11/2025
INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 20 novembre 2025, 22:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 [...]
Information on the total number of voting rights and shares
20/11/2025
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 20, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on [...]
Equillium to Participate in Upcoming Investor Conferences
20/11/2025
LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe [...]
Konica Minolta Healthcare Reinforces Leadership in Advanced Radiography with Seven Scientific Presentations on Dynamic Digital Radiography at RSNA 2025
20/11/2025
WAYNE, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc., a leader in medical diagnostic imaging and healthcare information technology, is pleased to announce seven scientific [...]
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
20/11/2025
—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinical Event Composite [...]
Syncromune®, Inc. to Present Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at the Society of Urological Oncology 26th Annual Meeting
20/11/2025
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Syncromune ® , Inc., a clinical-stage biopharmaceutical company pioneering SYNC-T, an in situ personalized combination immunotherapy [...]
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
20/11/2025
BELTSVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to [...]
Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1
20/11/2025
Evaxion’s AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program combining these novel AI- [...]
Catheter Precision Announces Successful LockeT Launch in South Africa
20/11/2025
FORT MILL, S.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac [...]
Valitor Announces Upcoming Presentation at the 15th Annual Ophthalmology Innovation Summit (OIS)
20/11/2025
BERKELEY, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced its chief executive officer, Gregory D. Kunst, will present [...]
Opus Genetics to Participate in Upcoming Investment Conferences
20/11/2025
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results
20/11/2025
– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels – – Positive outcomes [...]
Persephone Biosciences Announces Positive Topline Results from ARTEMIS Clinical Trial of First-of-its-kind Synbiotic for Children
20/11/2025
- 114 infants and toddlers received Persephone’s synbiotic or placebo - - The study generated important, positive clinical data on colonization and sleep improvement, after just 30 days of treatment - - Persephone’s [...]
4DMT to Participate in 8th Annual Evercore Healthcare Conference
20/11/2025
EMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
20/11/2025
HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
Nanox Announces Third Quarter of 2025 Financial Results and Provides Business Update
20/11/2025
Management to host conference call and webcast Thursday, November 20 , 2025, at 8:30 AM ET Company advances commercialization and is on track to meet year-end system deployment target PETAH TIKVA, Israel, Nov. 20, 2025 [...]
Shattuck Labs to Participate in Upcoming December Investor Conferences
20/11/2025
AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics [...]
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
20/11/2025
SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company [...]

Pages